Lipoprotein(a) and Cardiovascular Outcomes in Patient Prediabetes or Diabetes

Diabetes Care

42, 1312-1318

DOI: 10.2337/dc19-0274

Citation Report

#	Article	IF	Citations
1	Impact of free fatty acids on prognosis in coronary artery disease patients under different glucose metabolism status. Cardiovascular Diabetology, 2019, 18, 134.	6.8	20
2	Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?. Journal of Clinical Medicine, 2019, 8, 2073.	2.4	15
3	The Association of Lipoprotein(a) Plasma Levels With Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients With Type 1 Diabetes. Diabetes Care, 2020, 43, 1851-1858.	8.6	23
4	Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: a prospective, large cohort study. Journal of Translational Medicine, 2020, 18, 373.	4.4	9
5	Lipoprotein(a) and cardiovascular death in oldest-old (â‰¥80â€‰years) patients with acute myocardial infarction: A prospective cohort study. Atherosclerosis, 2020, 312, 54-59.	0.8	9
6	Long-term prognostic utility of low-density lipoprotein (LDL) triglyceride in real-world patients with coronary artery disease and diabetes or prediabetes. Cardiovascular Diabetology, 2020, 19, 152.	6.8	9
7	Association of plasma free fatty acids levels with the presence and severity of coronary and carotid atherosclerotic plaque in patients with type 2 diabetes mellitus. BMC Endocrine Disorders, 2020, 20, 156.	2.2	18
8	Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease. Journal of Lipid Research, 2020, 61, 1254-1262.	4.2	25
9	Serum lipoprotein (a) associates with a higher risk of reduced renal function: a prospective investigation. Journal of Lipid Research, 2020, 61, 1320-1327.	4.2	17
10	Recent trends in acute myocardial infarction among the young. Current Opinion in Cardiology, 2020, 35, 524-530.	1.8	22
11	Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study. Thrombosis and Haemostasis, 2021, 121, 1161-1168.	3.4	12
12	Heart-type fatty acid binding protein predicts cardiovascular events in patients with stable coronary artery disease: a prospective cohort study. Annals of Translational Medicine, 2020, 8, 1349-1349.	1.7	8
13	Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease. Heart, 2020, 106, 1228-1235.	2.9	28
14	Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease. Cardiovascular Diabetology, 2020, 19, 36.	6.8	24
15	The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes. Cardiovascular Diabetology, 2020, 19, 104.	6.8	42
16	Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study. Cardiovascular Diabetology, 2020, 19, 111.	6.8	24
17	Prognostic utility of heart-type fatty acid-binding protein in patients with stable coronary artery disease and impaired glucose metabolism: a cohort study. Cardiovascular Diabetology, 2020, 19, 15.	6.8	10
18	Predicting Cardiovascular Outcomes by Baseline Lipoprotein(a) Concentrations: A Large Cohort and Longâ€Term Followâ€up Study on Realâ€World Patients Receiving Percutaneous Coronary Intervention. Journal of the American Heart Association, 2020, 9, e014581.	3.7	37

#	Article	IF	Citations
19	Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. American Journal of Cardiology, 2020, 126, 94-102.	1.6	25
20	Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. Cardiovascular Diabetology, 2020, 19, 45.	6.8	44
21	Lipoprotein(a) in Patients With Type 2 Diabetes and Premature Coronary Artery Disease in the Coronary Care Unit. Heart Lung and Circulation, 2021, 30, 734-740.	0.4	5
22	The association between lipoprotein (a) and carotid atherosclerosis in patients with type 2 diabetes without pre-existing cardiovascular disease: A cross-sectional study. Diabetes Research and Clinical Practice, 2021, 171, 108622.	2.8	14
23	Atherogenic dyslipidaemia and cardiovascular events in patients with diabetes or pre-diabetes and stable coronary artery disease: a prospective, cohort study. BMJ Open, 2021, 11, e037340.	1.9	2
24	Prognostic value of NT-proBNP in patients with chronic coronary syndrome and normal left ventricular systolic function according to glucose status: a prospective cohort study. Cardiovascular Diabetology, 2021, 20, 84.	6.8	17
25	Visit-to-visit variability of lipid and cardiovascular events in patients with familial hypercholesterolemia. Annals of Translational Medicine, 2021, 9, 556-556.	1.7	0
26	Lipoprotein (a), hypertension, and cardiovascular outcomes: a prospective study of patients with stable coronary artery disease. Hypertension Research, 2021, 44, 1158-1167.	2.7	10
27	Effect of Lipoprotein (a) Levels on Long-term Cardiovascular Outcomes in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries. American Journal of Cardiology, 2021, 152, 34-42.	1.6	10
28	Managing dyslipidemia in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy, 2021, 22, 2221-2234.	1.8	14
29	Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study. Cardiovascular Diabetology, 2021, 20, 143.	6.8	22
30	Plasma lipoprotein(a) measured in the routine clinical care is associated to atherosclerotic cardiovascular disease during a 14-year follow-up. European Journal of Preventive Cardiology, 2022, 28, 2038-2047.	1.8	10
31	Coronary Artery Disease: Optimal Lipoprotein(a) for Survivalâ€"Lower Is Better? A Large Cohort With 43,647 Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 670859.	2.4	3
32	Association between new markers of cardiovascular risk and hepatic insulin resistance in those at high risk of developing type 2 diabetes. Endocrine, 2022, 75, 409-417.	2.3	3
33	Lipoprotein (a) and diabetes mellitus: causes and consequences. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 181-187.	2.3	13
34	Prognostic Significance of Preprocedural N-Terminal Pro-B-Type Natriuretic Peptide Assessment in Diabetic Patients With Multivessel Coronary Disease Undergoing Revascularization. Frontiers in Cardiovascular Medicine, 2021, 8, 721260.	2.4	3
35	Impact of lipoprotein(a) level on cardiometabolic disease in the Chinese population: The CHCNâ€BTH Study. European Journal of Clinical Investigation, 2022, 52, e13689.	3.4	4
36	Association of diabetes mellitus with clinical outcomes in patients with different coronary artery stenosis. Cardiovascular Diabetology, 2021, 20, 214.	6.8	8

#	Article	IF	Citations
37	Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 104-113.	2.3	2
38	Use of cardiovascular imaging in risk restratification of the diabetic patient. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 122-133.	2.3	2
39	Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle SociÃ©tÃ© Francophone dâ€™AthÃ©rosclÃ©rose (NSFA). Archives of Cardiovascular Diseases, 2021, 114, 828-847.	1.6	9
40	Association of Lipoprotein(a)-Associated Mortality and the Estimated Glomerular Filtration Rate Level in Patients Undergoing Coronary Angiography: A 51,500 Cohort Study. Frontiers in Cardiovascular Medicine, 2021, 8, 747120.	2.4	4
41	Lipoprotein (a)-mediated vascular calcification: population-based and in vitro studies. Metabolism: Clinical and Experimental, 2022, 127, 154960.	3.4	13
42	Baseline Low-Density-Lipoprotein Cholesterol Modifies the Risk of All-Cause Death Associated With Elevated Lipoprotein(a) in Coronary Artery Disease Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 817442.	2.4	2
43	Elevated lipoprotein(a) levels as an independent predictor of long-term recurrent events in patients with acute coronary syndrome. Coronary Artery Disease, 2022, Publish Ahead of Print, .	0.7	2
44	Association between triglyceride glucose index and carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China. Cardiovascular Diabetology, 2022, 21, 38.	6.8	25
45	Omega-3 fatty acids coordinate glucose and lipid metabolism in diabetic patients. Lipids in Health and Disease, 2022, 21, 31.	3.0	10
46	Elevated Lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: Insights from the REASSURE-NIRS registry. Atherosclerosis, 2022, 349, 183-189.	0.8	12
47	Non-alcoholic Fatty Liver Disease Is Associated With Cardiovascular Outcomes in Subjects With Prediabetes and Diabetes: A Prospective Community-Based Cohort Study. Frontiers in Cardiovascular Medicine, 2022, 9, 889597.	2.4	4
48	Association of C-peptide and lipoprotein(a) as two predictors with cardiometabolic biomarkers in patients with type 2 diabetes in KERCADR population-based study. PLoS ONE, 2022, 17, e0268927.	2.5	5
49	Lipoprotein (a) and diabetes mellitus. Atherosclerosis, 2022, 349, 63-71.	0.8	27
50	Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Different Metabolic Phenotypes. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	3
51	Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome. Journal of Translational Medicine, 2022, 20, .	4.4	10
52	Triglyceride glucose index for the detection of the severity of coronary artery disease in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China. Cardiovascular Diabetology, 2022, 21, .	6.8	37
53	Prevalence and Characteristics of Prediabetes and Metabolic Syndrome in Seemingly Healthy Persons at a Health Check-Up Clinic. Journal of Multidisciplinary Healthcare, 0, Volume 15, 1585-1594.	2.7	3
54	Clinical impact of blood pressure on cardiovascular death in patients 80 years and older following acute myocardial infarction: a prospective cohort study. Hypertension Research, 0, , .	2.7	2

#	Article	IF	Citations
55	New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e4281-e4294.	3.6	5
56	Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes. Journal of Thrombosis and Thrombolysis, 2022, 54, 382-392.	2.1	7
57	Associations of serum calcium/magnesium ratios with coronary artery disease in diabetes: a cross-sectional study. Postgraduate Medicine, 2023, 135, 72-78.	2.0	2
58	Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention. Atherosclerosis, 2022, 363, 109-116.	0.8	8
59	Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies. Journal of Clinical Medicine, 2022, 11, 6040.	2.4	14
60	What is responsible for acute myocardial infarction in combination with aplastic anemia? A case report and literature review. World Journal of Clinical Cases, 0, 10, 11955-11966.	0.8	1
61	Glucose metabolism status modifies the relationship between lipoprotein(a) and carotid plaques in individuals with fatty liver disease. Frontiers in Endocrinology, 0, 13, .	3.5	2
62	The value of HDL subfractions in predicting cardiovascular outcomes in untreated, diabetic patients with stable coronary artery disease: An age- and gender-matched case-control study. Frontiers in Endocrinology, 0, 13, .	3.5	1
63	Lipoprotein(a), Cardiovascular Events and Sex Differences: A Single Cardiological Unit Experience. Journal of Clinical Medicine, 2023, 12, 764.	2.4	0
64	Association between cumulative lipoprotein(a) exposure and adverse cardiovascular outcomes in patients with prediabetes or diabetes. IScience, 2023, 26, 106117.	4.1	0
65	Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states. Cardiovascular Diabetology, 2023, 22, .	6.8	9
66	What Is the Role of Aspirin in Primary Prevention in Patients With Elevated Lp(a)?. Cardiometabolic Syndrome Journal, 2023, 3, 41.	0.6	1
67	HbA1c-based rather than fasting plasma glucose-based definitions of prediabetes identifies high-risk patients with angiographic coronary intermediate lesions: a prospective cohort study. Cardiovascular Diabetology, 2023, 22, .	6.8	1
68	The prognostic effect of prediabetes defined by different criteria in patients with stable coronary artery disease: a prospective cohort study in Asia. European Journal of Preventive Cardiology, 2023, 30, 1418-1426.	1.8	5
69	Are we seeing the light at the end of the tunnel for high lipoprotein(a)? Lipoprotein(a). , 2022, 1, .		0
71	Association between the atherogenic index of plasma and carotid artery plaques in patients with coronary heart disease in different glucose metabolism states: an RCSCD-TCM study in Tianjin, China. Endocrine, 2023, 81, 252-261.	2.3	0
72	Epidemiology, Control, and Cardiovascular Outcomes of Dyslipidemia in Diabetes. Contemporary Diabetes, 2023, , 891-913.	0.0	0
73	Clinical Care of Lipids in People with Type 1 Diabetes. Contemporary Diabetes, 2023, , 755-778.	0.0	0

#	Article	IF	Citations
74	An In-Depth Prospective Comprehensive View on Myocardial Infarction (MI) in Younger Youth. Cureus, 2023, , .	0.5	0
75	Prognostic impacts of diabetes status and lipoprotein(a) levels in patients with ST-segment elevation myocardial infarction: a prospective cohort study. Cardiovascular Diabetology, 2023, 22, .	6.8	0
76	Lipoprotein(a) as a Higher Residual Risk for Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus than without. International Journal of General Medicine, 0, Volume 16, 3383-3391.	1.8	0
77	Determinants of incident atherosclerotic cardiovascular disease events among individuals with type 2 diabetic microvascular complications in the UK: a prospective cohort study. Diabetology and Metabolic Syndrome, 2023, 15, .	2.7	1
78	Lipoprotein(a) is associated with recurrent cardiovascular events in patients with coronary artery disease and prediabetes or diabetes. Journal of Endocrinological Investigation, 0, , .	3.3	5
79	Lipoprotein (a) in Cardiovascular Risk Assessment and Management in Diabetes Mellitus. , 0, , .		0
80	Burden of elevated lipoprotein(a) among patients with atherosclerotic cardiovascular disease: Evidence from a systematic literature review and feasibility assessment of meta-analysis. PLoS ONE, 2023, 18, e0294250.	2.5	1
81	Impact of High Lipoprotein(a) on Longâ€Term Survival Following Coronary Artery Bypass Grafting. Journal of the American Heart Association, 2024, 13, .	3.7	0
82	The relative and combined ability of stress hyperglycemia ratio and N-terminal pro-B-type natriuretic peptide to predict all-cause mortality in diabetic patients with multivessel coronary artery disease. Cardiovascular Diabetology, 2024, 23, .	6.8	0